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ABSTRACT  78 
Introduction: Serum liver biomarkers (gamma-glutamyl transferase, GGT; alanine aminotransferase, ALT; 79 
aspartate aminotransferase, AST; alkaline phosphatase, ALP; total bilirubin) are used as indicators of liver disease, 80 
but there is currently little data on their prospective association with risk of hepatobiliary cancers.  81 
Methods: A nested-case control study was conducted within the prospective EPIC cohort (>520,000 participants, 10 82 
European countries). After a mean 7.5 mean years of follow-up, 121 hepatocellular carcinoma (HCC), 34 83 
intrahepatic bile duct (IHBC) and 131 gallbladder and biliary tract (GBTC) cases were identified and matched to 2 84 
controls each. Circulating biomarkers were measured in serum taken at recruitment into the cohort, prior to cancer 85 
diagnosis. Multivariable adjusted conditional logistic regression was used to calculate odds ratios and 95% 86 
confidence intervals (OR; 95%CI).  87 
Results: In multivariable models, 1SD increase of each log-transformed biomarker was positively associated with 88 
HCC risk (OR(GGT)=4.23, 95%CI:2.72-6.59; OR(ALP)=3.43, 95%CI:2.31-5.10;OR(AST)=3.00, 95%CI:2.04-4.42; 89 
OR(ALT)=2.69, 95%CI:1.89-3.84; OR(Bilirubin)=2.25, 95%CI:1.58-3.20). Each liver enzyme (OR(GGT) =4.98; 90 
95%CI:1.75-14.17; OR(AST)=3.10, 95%CI:1.04-9.30; OR(ALT)=2.86, 95%CI:1.26-6.48, OR(ALP)=2.31, 91 
95%CI:1.10-4.86) but not bilirubin  (OR(Bilirubin)=1.46,95%CI:0.85-2.51) showed a significant association with 92 
IHBC. Only ALP was significantly associated with GBTC risk (OR(ALP)=1.59, 95%CI:1.20-2.09). 93 
Conclusion: This study shows positive associations between circulating liver biomarkers in sera collected prior to 94 
cancer diagnoses and the risks of developing HCC or IHBC, but not GBTC.  95 
Keywords: Hepatobiliary Cancer, Liver Function Test, Biological Markers, Prospective Cohort, Nested Case-96 
control Study 97 
 98 
 99 
 100 
 101 
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1. INTRODUCTION 104 
Liver cancer is the sixth most commonly diagnosed cancer and the second leading cause of cancer death worldwide 105 
[1]. Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is diagnosed at late stages and 106 
characterised by a poor prognosis [2]. Established HCC risk factors are chronic hepatitis B and C virus (HBV/HCV) 107 
infection, heavy alcohol drinking leading to liver cirrhosis, smoking and dietary aflatoxin exposure [3]. Important 108 
evidence from prospective studies also supports a role for diabetes and obesity-associated non-alcoholic fatty liver 109 
disease (NAFLD) as important HCC risk factors [4,5]. The group of intrahepatic bile duct (IHBC) and biliary tract 110 
cancers (GBTC; tumours of the gall bladder and extra-hepatic bile ducts) are anatomically related to HCC. They too 111 
are often diagnosed at late stages when prognosis is poor, also with little existing information about their key 112 
determinants [6].  113 
Liver function biomarkers (gamma-glutamyl transferase, GGT; alanine aminotransferase, ALT; aspartate 114 
aminotransferase, AST; alkaline phosphatase, ALP; total bilirubin) are used in clinical diagnosis of various 115 
disorders, including those related to liver function impairment and damage. Higher levels of specific combinations 116 
of these liver function biomarkers have been shown to be independently associated with NAFLD, liver cirrhosis, 117 
hepatitis infection, biliary obstruction [7] and diabetes risk [8,9], which is itself also associated with increased risk 118 
of HCC [10]. Previous case-control studies have found that GGT, ALT and AST are increased in approximately 119 
90% of diagnosed HCC cases while half of the cases also showed elevated liver-specific alkaline phosphatase (ALP) 120 
or bilirubin levels [11]. For bile duct cancers, the sparse available data suggest that approximately 70% of cases 121 
have elevated levels of ALP and GGT [12]. It is thus possible that alterations in liver function biomarkers occur 122 
during the early development of hepatobiliary cancers and may relate to some of the underlying mechanisms of 123 
tumour development at these sites. In a recent systematic review GGT but not ALT was associated with increased 124 
risk of overall and liver cancer but the geographical variations were observed for ALT [13].  Existing prospective 125 
observational studies investigating the association between liver function biomarkers and liver cancers have been 126 
mostly based on Asian populations [14,15], and/or limited only to particular enzymes (either transaminases, ALT 127 
and AST, or GGT) [16,17]. A cohort study based on a mostly hepatitis negative Taiwanese subjects measured only 128 
transaminases and found that both enzymes were good independent predictors for HCC development [16]. Other 129 
studies based on hepatitis infected Asian populations have found positive HCC risk associations with many liver 130 
enzymes, but not bilirubin [14,15]. In a Swedish cohort, higher GGT  levels were prospectively associated with 131 
increased risk for several cancer sites, including cancer in the liver, suggesting that this individual enzyme is not 132 
specific to disease in the liver and biliary tract [17]. However, there is currently little prospective data on this topic 133 
from additional Western populations where chronic hepatitis infections are less predominant while other HCC risk 134 
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factors such as excessive alcohol intake, obesity or diabetes are common. Very little is known about possible 135 
associations with IHBC or GBTC, particularly from prospective cohort settings. 136 
To address this, we aimed to evaluate associations between risk of HCC, IHBC and GBTC and five commonly 137 
measured liver function biomarkers (GGT, ALT, AST, ALP and bilirubin) using a nested case-control study within 138 
the large European Prospective Investigation into Cancer and Nutrition (EPIC) cohort,.  139 
2. MATERIALS AND METHODS 140 
2.1 Study design 141 
EPIC is a large multicentre prospective cohort study designed to investigate the association between diet, lifestyle 142 
and environmental factors and the incidence of various types of cancer and other chronic diseases. The rationale, 143 
study design and methods of recruitment are described in detail elsewhere [18,19]. Briefly, diet and lifestyle data 144 
were collected from approximately 520,000 men and women aged 20-85 years enrolled between 1992 and 2000 in 145 
23 centres throughout 10 European countries: Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, 146 
the Netherlands, and United Kingdom [18]. Blood samples were collected from most participants at recruitment and 147 
are stored at the International Agency for Research on Cancer (IARC, Lyon, France) in -196°C liquid nitrogen for 148 
all countries except Denmark (-150°C, nitrogen vapour) and Sweden (-80°C, freezers).  Study participants were 149 
recruited from the general population residing in a given geographical area, except for the Ragusa cohort (blood 150 
donors and their spouses), the Utrecht cohort (women attending a breast cancer screening), and the Oxford health 151 
conscious sub-cohort (mostly vegetarian and health-conscious volunteers).  152 
All cohort members provided written informed consent. Approval for this study was obtained from the relevant 153 
ethical review boards of the participating institutions and from the IARC ethical review board (Lyon, France).   154 
2.2 Follow-up for cancer incidence and mortality 155 
Vital status follow-up (98.5% complete) was collected by record linkage with regional and/or national mortality 156 
registries in all countries except Germany and Greece, where follow-up was based on active follow-up through 157 
study subjects or their next-of-kin. Cancer incidence was determined through record linkage with regional cancer 158 
registries (Denmark, Italy, Netherlands, Norway, Spain, Sweden and United Kingdom; complete up to December 159 
2006) or via a combination of methods, including the use of health insurance records, contacts with cancer and 160 
pathology registries, and active follow-up through study subjects and their next-of-kin (France, Germany, Greece; 161 
complete up to June 2010). 162 
2.3 Case Ascertainment  163 
According to the 10th revision of the International Statistical Classification of Diseases, Injury and Causes of Death 164 
(ICD10) HCC and IHBC were defined as C22.0 and C22.1, respectively. Biliary tract cancers (GBTC) included 165 
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tumours in the gallbladder (C23.9), extrahepatic bile ducts (C24.0), ampulla of Vater (C24.1), and biliary tract 166 
(C24.8 and C24.9). For each identified case, the histology and the methods used to diagnose the cancer were 167 
reviewed to exclude metastatic cases or other types of primary liver cancer.  168 
2.4 Nested Case-Control Study Design  169 
The design of the nested case-control study has been previously described in detail [20]. Briefly, 125 HCC, 35 170 
IHBC and 137 GBTC cases were identified during the period between participants’ recruitment and 2006 in EPIC. 171 
For each case, two controls were selected by incidence density sampling from all cohort members alive and free of 172 
cancer (except non-melanoma skin cancer), and matched by age at blood collection (±1 year), sex, study center, time 173 
of the day at blood collection (±3 hours), fasting status at blood collection (<3,3-6,and >6 hours); among women, 174 
additionally by menopausal status (pre-, peri-, and postmenopausal), and hormone replacement therapy use at time 175 
of blood collection (yes/no).   176 
2.5 Biomarker measures 177 
Hepatitis B and C virus seropositivity was detected in all case-control sets using the ARCHITECT HBsAg and anti-178 
HCV chemiluminescent microparticle immunoassays (CMIAs) from Abbott Diagnostics (Rungis, France). C- 179 
reactive protein (CRP), AFP, GGT, ALT, AST, ALP, total bilirubin and albumin were measured on the 180 
ARCHITECT c Systems™ and the AEROSET System (Abbott Diagnostics, Rungis, France) using standard 181 
protocols. All laboratory analyses were performed at the Centre de Biologie République laboratory, Lyon, France. 182 
Participants with missing blood sample or failed laboratory assay were excluded (n=4, 1, 6 for HCC, IHBC and 183 
GBTC, respectively). Therefore, the final sample size included 568 controls and 286 cases, among which there were 184 
121 HCC, 34 IHBC and 131 GBTC cases. 185 
2.6 Statistical Analyses 186 
Description of methods used for comparisons of baseline subjects characteristics, correlation and visualisation of 187 
biomarker levers over follow up time are described in electronic supplementary material. 188 
Conditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI) 189 
for serum individual biomarkers of interest (GGT, ALT, AST, ALP and bilirubin) in relation to HCC, IHBC and 190 
GBTC. Each main variable was included in models as categorical variables, with quartile cut-points based on sex-191 
specific distributions among controls (for HCC and GBTC) and continuous z-standardised (Mean=0, SD=1) value of 192 
each log-transformed biomarker for all cancer sites (to enable direct comparison between the biomarkers). To test 193 
dose-responses, trend variables were assigned the sex-specific median values for overall quartiles of the biomarkers. 194 
Cubic splines were constructed to illustrate the dose-response association between biomarker levels and HCC risk. 195 
In addition, specific ratios (AST/ALT; GGT/ALP), hepatic steatosis index (HSI) and score (see Table 1 footnotes), 196 
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and a score based on liver function biomarkers were calculated as described in more detail in supplementary 197 
material.  198 
For HCC, three conditional logistic models were used as follows: model 1) a model based on matching factors only; 199 
model 2) a multivariable model incorporating  additional adjustments for a priori defined confounders: smoking 200 
status (never, former, current, missing), baseline (continuous, g/d) and lifetime alcohol intake pattern (never, former, 201 
lifetime drinker and drinker only at recruitment), body mass index (BMI, continuous kg/m2), and physical activity 202 
(active, inactive, missing); model 3) a more detailed multivariable model incorporating the above variables as well 203 
as positivity status for hepatitis B and or C infection (yes, no, missing). Additionally, models 4 and 5 with separate 204 
incorporation of prevalent diabetes status at baseline and CRP to model 2 were explored.  205 
For IHBC and GBTC, only models 1 and 2 were considered, and a third model for GBTC with the additional 206 
adjustment for self-reported history of gallstones was run. Other potential confounders examined, but not included 207 
in the final models because their inclusion did not change the effect estimates by more than 10% were waist to hip 208 
ratio (WHR), coffee intake, and reported cardiovascular disease for HCC and IHBC or self-reported history of 209 
gallstones for GBTC. 210 
In sensitivity analyses, we excluded subjects with (a) self-reported diabetes at baseline (yes/no), because of the 211 
potential for modifications in diet after diagnosis of this disease, (b) hepatitis infection, since it is an established risk 212 
factor for liver cancers, (c) subjects with follow-up of <2/4 years after blood collection to exclude possible reverse 213 
causation, d) those with abnormal value of transaminases.  214 
For HCC, potential effect modification was studied for BMI, WHR and self-reported diabetes at baseline (since liver 215 
enzyme activity have been shown to increase in obesity and diabetes [22]), HSI score, smoking and alcohol intake 216 
(associated with liver cirrhosis [23]) and CRP, as a marker of chronic inflammation. Effect modification by these 217 
variables was tested on the multiplicative scale by including interaction terms formed by the product of modifying 218 
variable categories (see footnotes Table 1) and the value of categories of biomarkers. The statistical significance of 219 
interactions was assessed using likelihood ratio tests based on the models with and without the interaction terms. In 220 
our population only 21 cases and 12 controls within the same case-control sets had HSI below 30, a threshold for 221 
those that NAFLD can be ruled out [21], and statistical analyses were not possible in this sub-group.  222 
Receiver operating characteristics (ROC) curves were constructed for each individual biomarker of interest and their 223 
combinations in order to assess their discriminatory performance between cases and controls, for all subjects and 224 
stratified by HSI (see supplementary material). All statistical tests were two-sided, and P-values <0.05 were 225 
considered statistically significant. All statistical analyses were conducted using SAS version 9.2 software (SAS 226 
Institute, Inc., Cary, NC, USA).  227 
3. RESULTS 228 
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Selected baseline characteristics of cancer cases and their matched controls and correlations between variables are 229 
presented in Table 1 and Supplementary Tables 1 and 2. Supplementary Fig. 1 illustrates differences in 230 
biomarker levels between cases and controls over time. For the description see supplementary file.  231 
Table 1. Baseline demographic and lifestyle characteristics of HCC (N = 121), intrahepatic (N = 34) and extrahepatic (N = 232 
131) bile duct cancer cases and their matched controls in the EPIC nested case-control study. 233 
Characteristics 
Hepatocellular Carcinoma 
(HCC) 
Tumours of the Intrahepatic 
Bile Ducts (IHBC) 
Tumours of the Gallbladder 
and Extrahepatic Bile Ducts 
(GBTC) 
Cases 
 (N = 121) 
Matched 
controls 
 (N = 242) 
Cases 
 (N = 34) 
Matched 
controls  
(N = 67) 
Cases (N=131) 
Matched 
controls 
 (N = 259) 
Men, N (%) 82 (67.8) 165 (68.2) 18 (52.9) 35 (52.2) 58 (44.3) 112 (43.2) 
Age at blood donation (y) 60.2 ± 6.5 60 ± 6.7 61.6 ± 6.3 61.6 ± 6.2 58.6 ± 7.5 58.6 ± 7.5 
Follow-up from blood collection 
(y) 
4.99  ± 2.9 - 4.15 ± 2.21 - 5 ± 2.9 - 
Liver function and inflammatory biomarkers, median (5th, 95th%) 
 Gamma-glutamyl transferase 
(GGT), U/L 
84 (13, 742) 23.5 (10, 74) 44 (13, 595) 21 (11, 89) 23 (10, 99) 20 (10, 79) 
 Alanine aminotransferase 
(ALT), U/L 
30 (10, 151) 17 (9, 45) 20 (12, 99) 16 (9, 32) 17 (9, 39) 17 (9, 39) 
 
Aspartate aminotransferase  
(AST), U/L 
43 (14, 152) 19 (13, 35) 21 (15, 83) 18 (12, 26) 19 (12, 31) 18 (13, 30) 
 
Alkaline phosphatase (ALP), 
U/L 
84 (44, 173) 60 (38, 100) 74 (44, 380) 66 (41, 100) 66 (39, 110) 60 (36, 91) 
 Total billirubin, μmol/L 
10 (4, 32) 7.6 (3, 15) 7 (3, 17) 6.7 (3, 13) 7 (4, 14) 7 (3, 15) 
 C-reactive protein, mg/La 
2 (1, 27) 2 (1, 9) 3 (1, 19) 1 (1, 9) 2 (1, 13) 1 (1, 9) 
Liver function score, N (%)b 
 0 
52 (43.0) 231 (95.5) 19 (55.9) 55 (82.1) 111 (84.7) 220 (85.0) 
 ≥1 
69 (57.0) 11 (4.5) 15 (44.1) 12 (17.9) 20 (15.3) 39 (15.0) 
AST/ALT ratio, N (%)  
 ≤2 109 (90.1) 236 (97.5) 34 (100.0) 66 (98.5) 125 (95.4) 252 (97.3) 
 >2 12 (9.9) 6 (2.5) 0 (0.0) 1 (1.5) 6 (4.6) 7 (2.7) 
GGT/ALP ratio, N (%)  
 ≤2.5 104 (86.0) 238 (98.4) 33 (97.1) 67 (100.0) 130 (99.2) 255 (98.5) 
 >2.5 17 (14.0) 4 (1.6) 1 (2.9) 0 (0.0) 1 (0.8) 4 (1.5) 
No. with diabetes (N, %) c,d       
 No 101 (83.5) 219 (90.5) 31 (91.2) 61 (91.0) 116 (88.6) 228 (88.0) 
 Yes 16 (13.2) 14 (5.8) 2 (5.9) 4 (6.0) 8 (6.1) 15 (5.8) 
Hepatic steatosis index (HSI; N, 
%)escore 
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 ≤36 (unlikely NAFLD) 59 (48.8) 128 (52.9) 13 (38.2) 40 (59.7) 73 (55.7) 145 (60.0) 
 >36 (suspected NAFLD) 58 (47.9) 105 (43.4) 21 (61.8) 25 (37.3) 51 (37.2) 98 (37.8) 
Anthropometric factors and daily dietary intake, mean ± SD 
 Body mass index (BMI) f 
(kg/m2) 
28.1 (5.3) 27.0 (3.9) 28.2 (3.6) 26.4 (4.2) 26.8 (4.5) 26.4 (3.8) 
 Waist-to-hip ratio (WHR) g  0.93 (0.10) 0.91 (0.10) 0.90 (0.08) 0.89 (0.10) 0.88 (0.10) 0.87 (0.10) 
 Energy (kcal) 
2147.5 ± 
644.0 
2212.3 ± 
567.1 
2130.2 ± 
671.8 
1999.6 ± 
578.6 
2072.1 ± 619.5 
2089.3 ± 
570.9 
 Alcohol (g) 
19.7 ± 29.4 14.8 ± 18.2 14.1 ± 17.5 14.4 ± 18.1 13.4 ± 18.6 14.2 ± 18.6 
 Coffee consumption (g) 
398.2± 445.9 449.1± 434.8 398.1± 347.6 378.2± 359.8 378.8 ± 366.6 441.9±411.3 
Missing values were not excluded from percentage calculations, thus the sum of percents across sub-groups may not add up to 100%. 
Categorical variables are presented as numbers (percentages). 
Continuous variables are presented as mean ± standard deviations, except for liver function tests that are presented as median and (5th, 95th 
percentile). 
a CRP category: ≤3> 
b Ranges from 0 to 6; was grouped in categories as 0, 1-2, ≥3 abnormal liver function tests (ALT>55 U/L, AST>34 U/L, GGT men >64 
U/L, GGT women > 36 U/L, ALP > 150 U/L, albumin < 34 g/L, total bilirubin > 20.5 μmol/L; based on the values provided by the 
laboratory).  
c Self-reported. 
d Number of cases and controls with missing variable value: HCC = 13, IHBC = 3, and GBTC = 23. 
e Hepatic steatosis index (HSI) = 8 x ALT/AST ratio +BMI (+2, if diabetes;  +2, if female). Number of cases and controls with missing 
variable value: HCC =13, IHBC = 3, and GBTC = 23.  
f BMI categories: ≤ 25 normal, 25-30 overweight, ≥ 30 obese 
g WHR category: sex-specific tertiles (men: ≤0.92, 0.92-0.97, ≥0.97; women:≤ 0.77, 0.77-0.84, ≥ 0.84). 
 234 
3.1 Liver function biomarkers and the risk of liver (HCC, IHBC) and biliary tract cancers (GBTC) 235 
In the analyses by quartiles of serum enzyme levels, for all four enzymes and total bilirubin the highest quartile was 236 
significantly positively associated with HCC risk in both models 1 and 2 (Table 2). For model 2 the estimates were 237 
attenuated slightly than from those for model 1; comparing the highest quartile to the lowest quartile, the findings 238 
from model 2 were as follows: OR(GGT)=7.90, 95%CI:2.98-20.98, ptrend=<0.0001; OR(ALT)=4.62, 95%CI:2.05-10.41, 239 
ptrend=<0.0001; OR(AST)=5.00, 95%CI:1.95-12.86, ptrend=<0.0001; OR(ALP)=6.15, 95%CI:2.32-16.31, ptrend=<0.0001, 240 
OR(BILIRUBIN)= 3.22,95%CI:1.39-7.45, ptrend=0.0002. Further adjustment for hepatitis status slightly lowered the risk 241 
estimates for all enzymes. Only for ALP the OR was higher: OR(ALP)=9.56, 95%CI:2.63-34.72 and for bilirubin it was 242 
no longer significant.  243 
In continuous analyses, statistically significant positive associations were found between all liver enzymes and 244 
bilirubin and HCC (fully adjusted OR for 1 SD in log unit increase- model 2) (Table 2). GGT was most strongly 245 
related to HCC risk (OR(GGT)=4.23, 95%CI:2.72-6.59), followed by ALP (OR(ALP)=3.43, 95%CI:2.31-5.10), AST 246 
(OR(ALP)=3.00, 95%CI:2.04-4.42), ALT(OR(ALT)=2.69, 95%CI:1.89-3.84) and bilirubin (OR(BILIRUBIN)=2.25, 247 
95%CI:1.58-3.20). Further adjustment for hepatitis status (model 3) made these associations weaker for most enzymes 248 
and bilirubin (OR(GGT)=3.55, 95%CI:2.26-5.57), and stronger only for ALP (OR(ALP)=3.17, 95% CI:2.02-4.98). No 249 
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effect on the estimates was observed after additional adjustment for diabetes status or CRP (data not shown). Cubic 250 
splines illustrating dose-response associations between the biomarkers and HCC risk are presented in Fig. 1 (for 251 
GGT) and supplementary Fig. 3. 252 
Table 2. The association for HCC risk with individual liver function biomarkers for quartiles and per 1 SD increase of log-253 
transformed values.  254 
   Quartile 1  Quartile 2  
OR (95%CI) 
 Quartile 3  
OR (95%CI) 
 Quartile 4  
 OR (95%CI) 
  Per 1 SD* log-
transformed  
OR (95%CI) 
No. of cases/ 
controls 
11/60 10/59 10/56 90/67  121/242 
GGT       
 Model 1 1.00 (Ref) 1.04 (0.38, 2.84) 1.06 (0.39,2.90) 9.10 (3.93,21.10) <.0001 4.58 (3.04,6.90) 
 Model 2 1.00 (Ref) 1.16 (0.37, 3.67) 1.12 (0.33,3.76) 7.90 (2.98,20.98) <.0001 4.23 (2.72,6.59) 
 Model 3 1.00 (Ref) 1.18 (0.35, 4.02) 1.14 (0.33,4.03) 5.70 (1.99,16.31) <.0001 3.55 (2.26,5.57) 
ALT       
 Model 1 1.00 (Ref) 0.97 (0.41, 2.30) 2.31 (1.03,5.21) 5.10 (2.44,10.67) <.0001 2.77 (2.03,3.77) 
 Model 2 1.00 (Ref) 0.77 (0.28, 2.12) 1.87 (0.74,4.76) 4.62 (2.05,10.41) <.0001 2.69 (1.89,3.84) 
 Model 3 1.00 (Ref) 2.04 (0.71, 5.85) 0.79 (0.24,2.60) 3.03 (1.14,8.09) 0.0015 2.04 (1.40,2.99) 
AST       
 Model 1 1.00 (Ref) 1.94 (0.76, 4.92) 1.15 (0.43,3.06) 6.27 (2.66,14.82) <.0001 3.25 (2.31,4.59) 
 Model 2 1.00 (Ref) 1.96 (0.70, 5.48) 0.86 (0.28,2.60) 5.00 (1.95,12.86) <.0001 3.00 (2.04,4.42) 
 Model 3 1.00 (Ref) 2.04 (0.71, 5.85) 0.79 (0.24,2.60) 3.03 (1.14,8.09) 0.0028 3.17 (2.02,4.98) 
ALP       
 Model 1 1.00 (Ref) 0.80 (0.30, 2.14) 1.35 (0.55,3.32) 5.97 (2.60,13.67) <.0001 3.85 (2.65,5.59) 
 Model 2 1.00 (Ref) 1.01 (0.34, 3.02) 1.82 (0.67,4.97) 6.15 (2.32,16.31) <.0001 3.43 (2.31,5.10) 
 Model 3 1.00 (Ref) 1.20 (0.33, 4.39) 5.85(1.44,23.81) 9.56 (2.63,34.72) <.0001 2.75 (1.81,4.18) 
Bilirubin       
 Model 1 1.00 (Ref) 0.72 (0.35, 1.52) 1.03 (0.47,2.23) 2.89 (1.44,5.80) <.0001 2.04 (1.54,2.70) 
 Model 2 1.00 (Ref) 0.64 (0.27, 1.49) 1.40 (0.56,3.48) 3.22 (1.39,7.45) 0.0002 2.25 (1.58,3.20) 
 Model 3 1.00 (Ref) 0.52 (0.20, 1.35) 1.04 (0.38,2.86) 2.20 (0.88,5.50) 0.0206 2.06 (1.40,3.03) 
Model 1: matching factors: age at blood collection (±1 year), sex, study center, time of the day at blood collection (±3 hours), fasting 
status at blood collection (<3,3-6,and >6 hours); among women, additionally by menopausal status (pre-, peri-, and postmenopausal), 
and hormone replacement therapy use at time of blood collection (yes/no). 
Model 2: model 1 + smoking status (never, former, current, missing), baseline (continuous, g/d) and lifetime alcohol intake pattern 
(never, former, lifetime drinker and drinker only at recruitment), body mass index (BMI, continuous kg/m2), and physical activity 
(active, inactive, missing). 
Model 3: model 2 + plus hepatitis 
Cut-off values for sex-specific quartiles: 
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GGT- females (<14, <=14-18; >=18-26, >=26 U/L), males (<18.5, >=18.5-26.5,>=26.5- 41.5, >=41.5 U/L) 
AST- females (<15, >=15-18; >=18-21, >=21 U/L), males (<16, >=16-19; >=19-24, >=24U/L) 
ALP- females (<51, >=51-64; >=64-77, >=77 U/L), males (<49, >=49-58; >=58-68, >=68 U/L) 
ALT- females (<11, >=11-15; >=15-20, >=20U/L), males (<15, >=15-19; >=19-26, >=26U/L) 
Bilirubin- females (<5.3, >=5.3-6.7; >=6.7-8.5, >=8.5U/L), males (<6, >=6-7.75; >=7.75-10.2, >=10.2 U/L) 
* ܵܦ୪୭୥ሺீீ்ሻ ൌ 1.03, ܵܦ୪୭୥ሺ஺௅்ሻ ൌ 0.68, ܵܦ୪୭୥ሺ஺ௌ்ሻ ൌ 0.61, ܵܦ୪୭୥ሺ஺௅௉ሻ ൌ 0.39, ܵܦ୪୭୥ሺ஻௜௟௜௥௨௕௜௡ሻ ൌ 0.54 
 255 
Fig.1 Dose- response association for log-transformed GGT levels and HCC risk. Adjusted OR (solid line) and 95%CI 256 
(dashed lines) were constructed with 3 knots with the reference value set as median. 257 
 258 
For IHBC, all of the enzymes but not bilirubin showed a significantly positive association in the multivariable 259 
continuous model (model 2: OR(GGT)=4.98, 95%CI:1.75-14.17, OR(ALT)=2.86, 95%CI:1.26-6.48, OR(AST)=3.10, 260 
95%CI:1.04-9.30, OR(ALP)=2.31, 95%CI:1.10-4.86) (Table 3).  261 
Table 3. The association of serum liver enzyme levels with IHBC risk per 1 SD increase of log-transformed values. 262 
 Model 1 
OR (95%CI) 
Model 2 
OR (95%CI) 
No. of cases/controls 34/67 34/67 
GGT 3.74 (1.73,8.11) 4.98 (1.75,14.17) 
ALT 2.55 (1.34,4.86) 2.86 (1.26,6.48) 
AST 3.18 (1.24,8.13) 3.10 (1.04,9.30) 
ALP 2.24 (1.20,4.20) 2.31 (1.10,4.86) 
Bilirubin 1.36 (0.87,2.13) 1.46 (0.85,2.51) 
Data are log-transformed and z-standardised to 1SD and a mean of 0. 
Model 1: matching factors: age at blood collection (±1 year), sex, study 
center, time of the day at blood collection (±3 hours), fasting status at blood 
collection (<3, 3-6, and >6 hours); among women, additionally by 
menopausal status (pre-, peri-, and postmenopausal), and hormone 
replacement therapy use at time of blood collection (yes/no). 
Model 2: model 1 + smoking status (never, former, current, missing), 
baseline (continuous, g/d) and lifetime alcohol intake pattern (never, former, 
lifetime drinker and drinker only at recruitment), body mass index (BMI, 
continuous kg/m2), and physical activity (active, inactive, missing). 
* ܵܦ୪୭୥ሺீீ்ሻ ൌ 0.87, ܵܦ୪୭୥ሺ஺௅்ሻ ൌ 0.56, ܵܦ୪୭୥ሺ஺ௌ்ሻ ൌ 0.45, ܵܦ୪୭୥ሺ஺௅௉ሻ ൌ
0.43, ܵܦ୪୭୥ሺ஻௜௟௜௥௨௕௜௡ሻ ൌ 0.48 
 263 
For GBTC, only ALP was significantly associated with higher GBTC risk (model 2: OR(ALP)=2.80, 95%CI:1.36-264 
5.76, ptrend =0.144 for the highest quartile and OR(ALP)=1.59, 95%CI:1.20-2.09 per 1SD increase of log-transformed 265 
value) (Table 4).  266 
Table 4. The association for GBTC risk with individual liver function biomarkers for quartiles and per 1 SD increase of 267 
log-transformed values. 268 
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   Quartile 1  Quartile 2  
OR (95%CI) 
 Quartile 3 
OR (95%CI) 
  
 Quartile 4 
OR (95%CI) 
  
  Per 1 SD log-
transformed  
OR (95%CI) 
No. of 
cases/controls 
29/62 30/72 28/58 44/66  131/259 
GGT   
 Model 1 1.00 (Ref) 0.96 (0.50,1.85) 1.08 (0.55,2.13) 1.53 (0.80,2.92) 0.054 1.20 (0.94,1.53) 
  Model 2 1.00 (Ref) 0.90 (0.46,1.76) 1.12 (0.55,2.24) 1.50 (0.76,2.98) 0.056 1.20 (0.93,1.56) 
ALT   
 Model 1 1.00 (Ref) 0.96 (0.50,1.84) 1.28 (0.67,2.43) 1.22 (0.61,2.45) 0.361 1.10 (0.87,1.40) 
  Model 2 1.00 (Ref) 0.91 (0.46,1.78) 1.28 (0.66,2.48) 1.16 (0.55,2.44) 0.430 1.09 (0.85,1.41) 
AST   
 Model 1 1.00 (Ref) 0.86 (0.46,1.63) 0.73 (0.36,1.47) 1.07 (0.53,2.16) 0.542 1.13 (0.90,1.43) 
  Model 2 1.00 (Ref) 0.87 (0.46,1.65) 0.70 (0.34,1.42) 1.12 (0.55,2.32) 0.492 1.17 (0.92,1.50) 
ALP   
 Model 1 1.00 (Ref) 1.18 (0.60,2.33) 1.72 (0.85,3.47) 2.71 (1.37,5.36) 0.183 1.57 (1.21,2.04) 
  Model 2 1.00 (Ref) 1.14 (0.56,2.35) 1.70 (0.81,3.56) 2.80 (1.36,5.76) 0.144 1.59 (1.20,2.09) 
Bilirubin   
 Model 1 1.00 (Ref) 0.74 (0.41,1.34) 0.74 (0.38,1.42) 1.05 (0.55,1.99) 0.768 1.01 (0.80,1.27) 
  Model 2 1.00 (Ref) 0.69 (0.37,1.28) 0.71 (0.35,1.44) 1.18 (0.59,2.35) 0.474 1.06 (0.83,1.36) 
Model 1: matching factors: age at blood collection (±1 year), sex, study center, time of the day at blood collection (±3 hours), 
fasting status at blood collection (<3, 3-6, and >6 hours); among women, additionally by menopausal status (pre-, peri-, and 
postmenopausal), and hormone replacement therapy use at time of blood collection (yes/no). 
Model 2: model 1 + smoking status (never, former, current, missing), baseline (continuous, g/d) and lifetime alcohol intake pattern 
(never, former, lifetime drinker and drinker only at recruitment), body mass index (BMI, continuous kg/m2), and physical activity 
(active, inactive, missing). 
Cut-off values for sex-specific quartiles: 
GGT- females (<14, <=14-18; >=18-26, >=26 U/L), males (<18.5, >=18.5-26.5,>=26.5- 41.5, >=41.5 U/L) 
AST- females (<15, >=15-18; >=18-21, >=21 U/L), males (<16, >=16-19; >=19-24, >=24U/L) 
ALP- females (<51, >=51-64; >=64-77, >=77 U/L), males (<49, >=49-58; >=58-68, >=68 U/L) 
ALT- females (<11, >=11-15; >=15-20, >=20U/L), males (<15, >=15-19; >=19-26, >=26U/L) 
Bilirubin- females (<5.3, >=5.3-6.7; >=6.7-8.5, >=8.5U/L), males (<6, >=6-7.75; >=7.75-10.2, >=10.2 U/L) 
* ܵܦ୪୭୥ሺீீ்ሻ ൌ 0.66, ܵܦ୪୭୥ሺ஺௅்ሻ ൌ 0.45, ܵܦ୪୭୥ሺ஺ௌ்ሻ ൌ 0.30, ܵܦ୪୭୥ሺ஺௅௉ሻ ൌ 0.31, ܵܦ୪୭୥ሺ஻௜௟௜௥௨௕௜௡ሻ ൌ 0.42 
 269 
3.2 Interactions and sensitivity analyses 270 
For HCC, an interaction was observed for WHR category with GGT category (p=0.013), but not for categories of 271 
BMI (p=0.605), HSI (p=0.508), CRP (p=0.079), baseline alcohol intake (p=0.413) or intake pattern (p=0.717), sex 272 
(p=0.202), diabetes (p=0.366) or smoking status (0.866). In analyses stratified by WHR category, the strongest HCC 273 
risk was observed in crude models for the highest WHR tertile (OR=5.91; 95%CI:2.78-12.55). For ALP, an 274 
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interaction was observed between the ALP quartiles and sex (p=0.0004). In the subgroup analyses, in men the 275 
highest ALP quartile exhibited a significantly higher risk of HCC (OR= 6.15; 95%CI:2.32-16.31), but this positive 276 
association was not significant for women in crude models (OR= 2.71; 95%CI:0.49-14.91). There was an interaction 277 
between AST category and alcohol drinking pattern (p=0.027). Due to low numbers of subjects, especially for 278 
controls in the former drinkers category, it was not possible to conduct subgroup analyses by alcohol intake pattern. 279 
No significant interactions existed for ALT.  280 
No attenuation of the estimates was observed after excluding the first 2/4 years of follow-up. After excluding 281 
individuals with positive hepatitis status, prevalent diabetes or suspected NAFLD, the significant outcomes 282 
remained. All liver functions biomarkers but bilirubin also remained statistically significant for HCC in the 283 
subgroup of individuals with suspected NAFLD (HSI>36) (not shown). Interestingly for GBTC, GGT reached the 284 
significance only for HSI≤36 subgroup (OR=1.93; 95%CI=1.12-3.33). When abnormal transaminases levels were 285 
excluded (ALT <55 U/L and AST <34 U/L), the OR were: 1.85(95%CI:1.00-3.43) for GGT, 1.50(95%CI:0.82-2.74) 286 
for ALP and 1.24(95%CI:0.73-2.10) for bilirubin, but remaining numbers of cases/controls were low, i.e. 55/98.  287 
4. DISCUSSION 288 
In this study, all of the measured liver enzymes (GGT, ALT, AST, ALP) and total bilirubin were shown to be 289 
positively associated with HCC risk. For IHBC, increases in the enzymes, but not bilirubin, were associated with 290 
higher risk. But for GBTC, which includes cancers of gallbladder and extra-hepatic bile ducts, only ALP showed a 291 
statistically significant association.  Assessment of liver function markers can provide meaningful insight into the 292 
clinical condition of the liver, including cholestasis. For this reason, such markers are commonly measured in 293 
clinical practice. But, there is on-going discussion as to whether some, such as GGT, are simply risk markers or 294 
causally involved. GGT has been related to oxidative stress due to its role in glutathione (GSH) degradation, which 295 
may create a cancer-promotive environment in the surrounding tissues [24], and in the liver [25]. There is also 296 
evidence showing an elevation of GGT in obese or diabetic patients or those with liver steatosis [26]. These 297 
disorders are related to the metabolic syndrome which has itself  also been associated with increased HCC risk [5]. 298 
A main limitation of our study is the lack of information on liver diseases, such as steatosis or cirrhosis. We 299 
attempted to address this in our analyses by controlling for some conditions that may be related to these syndromes 300 
(e.g. hepatitis infection status, alcohol intake, BMI, WHR, self-reported history of diabetes or cardiovascular 301 
disease, CRP level and calculated hepatic steatosis index). However, we did not observe appreciable confounding 302 
for these factors, except for WHR. This may suggest that abdominal obesity and obesity-associated chronic 303 
inflammation and oxidative stress [27], may in large part drive this association. 304 
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Individually, liver function biomarkers lack specificity and their abnormal measures may be indicative of either 305 
hepatic [28] and/or extra-hepatic disorders, but also underlying cholestasis, biliary obstruction or bile duct 306 
inflammation [7,29]. Transaminases (AST and ALT), that we identified as positively associated with cancers located 307 
within the liver (HCC, IHBC), are mostly of hepatic origin, located in intracellular compartments and typically 308 
related to hepatic injury from either hepatitis infection, NAFLD, liver cirrhosis or other causes [29]. ALT is 309 
expressed mainly in the liver and is most specific indictor of liver injury [29]. ALP is produced in the membranes of 310 
cells lining bile ducts [28] and appears elevated in extrahepatic disease. The positive association of ALP with GBTC 311 
risk may be due to chronic inflammation in the bile ducts [29], which then affects liver function, but this requires 312 
further testing and assessment. In contrast, GGT is expressed on the cell surface and thus is released to the 313 
circulation quicker than the other enzymes in case of hepatic injury [24]. GGT is characterised by a high sensitivity 314 
but a low specificity to a particular disease of hepatobiliary tract, however in conjunction with ALP they may 315 
suggest chronic inflammation in the bile ducts of hepatic origin [29]. In our study, GGT showed the strongest 316 
association with HCC risk out of all the biomarkers assessed, consistent with previous observations on hepatitis 317 
infected subjects [14]. As for total bilirubin, although its elevated levels have been seen in hepatic failure in 318 
conjunction with other liver biomarkers [7], there is some evidence suggestive of an inverse association with 319 
colorectal,  lung and breast cancer risk or mortality, likely due to its antioxidant properties [30-32]  . In this study we 320 
observed a positive association with total bilirubin.  The liver is involved in bilirubin metabolism, particularly its 321 
conjugation. Hence, it could be assumed that liver dysfunction may result in higher circulating bilirubin 322 
concentrations due to some underlying liver disease process [33]. It follows that observed HCC risk associations for 323 
bilirubin could then be positive. Indeed, abnormal high bilirubin levels (≥1.5 mg/dL) have been shown in previous 324 
studies to be correlated with HCC aggressiveness [34]. Elevated bilirubin levels (1.5-9 mg/dL) with all other liver 325 
enzymes being normal or in the absence of liver disease are generally indicative of benign hereditary 326 
hyperbilirubinemia (Gilbert Syndrome). This is caused by a reduced activity of the liver enzyme uridine 327 
diphosphate-glucuronosyltransferase-1 [35]. In such a case, bilirubin is proposed to have cancer-protective 328 
properties, which is currently being investigated in ongoing epidemiological studies. 329 
It is interesting that, as illustrated by the Loess curves, all of the biomarkers were higher in the HCC cases 330 
throughout the follow up period suggesting underlying physiological changes related to liver function long before 331 
clinical diagnosis. For example, elevation of liver enzymes and bilirubin has been observed in primary sclerosing 332 
cholangitis (PSC). PSC may lead to inflammatory damage of bile ducts both inside and outside of the liver, blocking 333 
the flow of bile, causing cholestasis and, finally, leading to biliary cirrhosis and liver failure [36]. Clinical guidelines 334 
also indicate that a ratio of AST/ALT above 2 may suggest alcoholic liver disease [7], and that GGT/ALP ratio 335 
above 2.5 may indicate alcoholic liver cirrhosis [37,28]. In our study having AST/ALT above 2 was associated with 336 
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over five-fold higher HCC risk, and for subjects in the upper category for GGT/ALP (>2.5) the HCC risk was eight 337 
times higher than for the lower category. Although our observations are in line with what is known about the natural 338 
history of HCC development, it is interesting that the individual associations that we observed were maintained after 339 
adjustment for patterns of alcohol intake and levels of consumption.  340 
A limitation of this study is a low number of cancer cases, which is a consequence of its prospective design wherein 341 
participants were recruited into the cohort prior to cancer development and followed over time, and the low 342 
incidence of the diseases studied. We also had no data on liver cirrhosis, NAFLD, NASH or steatosis that may partly 343 
mediate the observed associations. The possibility of reverse causation cannot be excluded, as is probably the case 344 
for any epidemiological study even those based on prospective designs However, we did carefully assess potential 345 
confounding and effect modification by metabolic markers that may be related to hepatic disorders (HSI, hepatitis, 346 
prevalent diabetes status, and numerous metabolic biomarkers), as well as level/patterns of alcohol consumption that 347 
may be related to development of liver cirrhosis. In sensitivity analyses, we also excluded the first two years of 348 
follow up and did not observe any change in the findings, suggesting that the observed alterations are early events.  349 
Lastly, all of the information and the biological samples were collected at baseline only and it is possible that dietary 350 
and lifestyle factors were modified during the follow up period affecting metabolic processes. The key strengths of 351 
our study include its prospective design and collection of detailed lifestyle information enabling adjustment for 352 
multiple confounders. We also evaluated the whole spectrum of enzymes and bilirubin, and had available 353 
prospectively measured hepatitis infection markers that could give a good picture of hepatic metabolic changes.  354 
In conclusion, this study shows that all individually elevated liver enzymes and total bilirubin are good pre-355 
diagnostic markers of cancers located within the liver (HCC, IHBC), but not in extra-hepatic compartments of 356 
hepatobiliary tract (GBTC). The study identified the most HCC-discriminant liver function biomarkers. A clinical 357 
validation study based on different patient cohorts with available markers for liver steatosis or fibrosis, i.e. in high 358 
risk individuals, would be valuable in order to test the clinical significance of this specific marker for population risk 359 
stratification and risk prediction modelling for early diagnosis. 360 
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Additional statistical analyses 
Description of the study population and biomarker levels for different follow up times for HCC risk  
Comparisons of the baseline subject characteristics were done using the t-test for continuous variables and the chi-
square test for categorical variables. Age-, sex-, fasting status-, hepatitis infection- and smoking-adjusted 
Spearman’s partial correlation coefficients were used to assess the correlations between biomarkers studied (liver 
enzymes and bilirubin) and selected risk factors among controls. Differences in natural log-transformed biomarker 
levels according to different strata of variables of interest, stratified by sex, and adjusted for BMI, fasting status and 
country were assessed by generalized linear model (GLM). To visualize biomarker level over follow up time, Loess 
curves separate for cases and controls were presented for each enzyme, bilirubin and AFP by the time of follow up. 
For better visualization, the reference follow up time was assigned to the control subjects based on the follow up 
time of their corresponding cases. 
Additional analyzes- biomarker ratios, liver function score and hepatic steatosis index (HSI) 
The analyses for HCC and GBTC were conducted separately for men and women. Ratios of AST/ALT and 
GGT/ALP, used as supporting indicators of the source of liver disease, were calculated and categorised. The cut-off 
values for AST/ALT and GGT/ALP categories were 2 and 2.5, respectively, suggesting alcohol-related causes [24]. 
A liver function score (0-6) was constructed based on our data summarizing the number of abnormal values for five 
liver function tests (ALT>55 U/L, AST>34 U/L, GGT men>64 U/L, GGT women>36 U/L, ALP>150 U/L, 
bilirubin>20.5 μmol/L and albumin < 34 g/L; cut-points based directly on assay specifications). For biomarker level 
above the clinical threshold a mark of 1 was assigned, and 0 if the biomarker level was below this threshold. Two 
categories were constructed based on this score: a reference category with none biomarkers elevated (score=0) and a 
category of one and more elevated biomarkers (score 1-6), suggesting possible impaired liver function. Hepatic 
steatosis index (HSI) score was calculated based on the threshold (≤36>), which is the cut-off value for assessment 
of possible NAFLD. The association of liver function and HSI score and the ratios categories with risk of HCC, 
IHBC and GBTC was also calculated using conditional logistic regression models. Due to very low numbers of 
control participants with enzyme levels above the clinical threshold we were unable to obtain estimates for 
dichotomised variable of under- above- this threshold of each biomarker.  
Discriminatory accuracy of the models- ROC curves  
Receiver operating characteristics (ROC) curves were constructed for each individual biomarker of interest and their 
combinations. In order to reduce bias, the dataset was randomly split into training (60%, 70 cases and 141 controls) 
and testing (40%, 51 cases, 101 controls) components. Using the training component, the best discriminatory model 
between cases and controls based on liver function biomarkers was selected according to the area under the ROC 
curves (AUROC) using a stepwise selection method. In exploratory analyses we further applied the selected models 
by time of follow up (cut-offs 1 and 2 years) and in hepatitis free subjects (to exclude potential effect of hepatitis 
infection on liver enzyme levels). Due to sample size limitation of the training and testing subgroups, the 
exploratory analyses were conducted on the total number of cases and controls. The models were considered ranked 
as excellent (AUROC greater than 90%), good (AUROC above 80%), fair (AUROC below 80%), and poor 
(AUROC less than 70%). 
Supplementary Results 
Description of the study population 
More than 70% of HCC cases had at least one abnormal liver function test whereas the percentages for IHBC and 
GBTC cases were 46% and 15%, respectively. Observed correlations between liver biomarkers, dietary intakes and 
anthropometric measures among controls are presented in Supplementary Table 2. Liver enzymes correlated with 
each other, CRP and albumin, but also body fatness measures and alcohol intake. Serum liver enzyme levels 
according to different strata of variables of interest are presented in Supplementary tables 3-6. 
Biomarker levels for different follow-up times for HCC  
As assessed by visual inspection of Loess curves, the levels of all standardised enzymes were lower for HCC 
controls than the cases for different follow-up periods of their cases (Supplementary Fig. 1). For GGT and AST the 
case-control difference became more pronounced closer to the time of diagnosis, especially within 2.5 years. Similar 
but less clear pattern was seen for bilirubin and ALT, but not for AFP, for which the levels were higher only within 
the 2.5 years prior to HCC diagnosis.   
Additional analyses 
Adjustment for self-reported history of gallstones did not alter the findings. For both HCC and GBTC, findings were 
similar in men and women (Supplementary Tables 7 and 8). The estimates for the liver function score based on 
abnormal values of liver enzymes, bilirubin and albumin, as well as for enzyme ratio categories (AST/ALT and 
GGT/ALP) and HSI, in relation to HCC, IHBC and GBTC are presented in Supplementary Table 9. Significantly 
positive associations for subjects with at least one abnormal liver function test in multivariable model were observed 
for HCC and IHBC and for the ratios for HCC. No significant associations were observed for HSI in multivariable 
adjusted models. 
Discriminatory accuracy of the models- ROC curves  
ROC was used to illustrate changes in model discriminatory accuracy by comparing AUROC among individual 
biomarkers and their combinations. For individual enzymes in relation to HCC, AUROC was the highest 82% for 
GGT, AST and ALP followed by AFP (80%), ALT (75%) and bilirubin (73%). For the combination of biomarkers 
after stepwise selection the best performance was observed for GGT, AST and ALP (AUROC=0.88, 95%CI:0.82-
0.94), suggesting that these are most HCC-specific biomarkers. Addition of ALT and/or bilirubin did not further 
improve the model. Excellent predictive accuracy was observed within the 1st year of follow up. In this subset, the 
discriminatory accuracy based on the model including the three enzymes was 93% (AUROC=0.93, 95%CI:0.85-
1.00). The exclusion of subjects diagnosed within 1or 2 years of recruitment had lower, but still good discriminatory 
power (82 and 83%, respectively). In subgroup analyses by HSI, discriminatory power for the combination of the 3 
biomarkers was 79 and 86% for those with unlikely and suspected NAFLD, respectively, indicating its good 
performance in both healthy and higher HCC risk individuals.  In hepatitis free individuals, as based on the full 
complement of cases and matched controls, the accuracy of this model showed a fair performance; model based on 
GGT, AST and ALP differentiated cases from controls with 78% accuracy. The prediction models performed only 
fair for IHBC and poor for GBTC for which weaker or no associations were observed. 
A biomarker based on the sum of these biomarkers (GGT, ALT and AST) increased HCC risk by 90% (34-134%), 
even if hepatic, diabetic or participants with suspected NAFLD were only considered. Only exclusion of obese 
participants attenuated the significance (OR= 4.17; 95%CI: 0.51- 34.20). In subset of obese subjects similar risk 
increase to the whole cohort was observed (OR= 1.93; 95%CI: 1.41- 2.63). This biomarker could be potentially used 
to identify which obese individuals should be referred for screening of HCC.  
 
 Supplementary tables 
Supplementary table 1: Baseline demographic and lifestyle characteristics of HCC (N = 121), intrahepatic (N = 34) and gallbladder and extrahepatic (N = 131) bile duct cancer cases and 
their matched controls in the EPIC nested case-control study. 
Characteristics 
Hepatocellular Carcinoma (HCC) Tumours of the Intrahepatic Bile Ducts (IHBC) 
Tumours of the Gallbladder and 
Extrahepatic Bile Ducts (GBTC) 
Cases (N = 121) Matched controls  (N = 242) Cases (N = 34) 
Matched controls  
(N = 67) Cases (N=131) 
Matched controls 
(N = 259) 
Smoking status (N, %) a 
Never smoker 33 27.3 104 43.0 16 47.1 29 43.3 57 43.5 123 47.5 
Former smoker 39 32.2 91 37.6 9 26.5 14 20.9 38 29.0 81 31.3 
Current smoker 47 38.8 46 19.0 8 23.5 20 29.9 35 26.7 53 20.5 
No. with gallstones (N,  %) b 
No 74 61.2 154 63.6 17 50 42 62.7 69 52.7 148 57.1 
Yes 15 12.4 24 9.9 7 20.59 3 4.5 13 9.9 13 5.0 
Total physical activity (N,  %) c 
Inactive 11 9.1 33 13.6 5 14.7 6 9.0 20 15.3 37 14.3 
Moderately inactive 37 30.6 72 29.8 11 32.4 21 31.3 43 32.8 83 32.0 
Moderately active 68 56.2 129 53.3 15 44.1 36 53.7 62 47.3 127 49.0 
Alcohol consumption at recruitment, g/d (N, % ) 
None 30 24.8 22 9.1 7 20.6 11 16.4 21 16.0 34 13.1 
0.1-6 33 27.3 77 31.8 10 29.4 24 35.8 45 34.4 86 33.2 
6.1-12 12 9.9 43 17.8 3 8.8 3 4.5 23 17.6 33 12.7 
12.1-24 15 12.4 49 20.2 6 17.7 14 20.9 20 15.3 62 23.9 
24.1-60 19 15.7 40 16.5 8 23.5 13 19.4 14 10.7 33 12.7 
>60 12 9.9 11 4.5 0 0 2 3.0 8 6.1 11 4.2 
Drinking history (N, %) 
Never drinker 12 9.9 19 7.9 6 17.6 10 14.9 12 9.2 23 8.9 
Former drinker 18 14.9 3 1.2 1 2.9 1 1.5 8 6.1 9 3.5 
Drinker at recruitment 21 17.4 52 21.5 5 14.7 10 14.9 36 27.5 78 30.1 
Lifetime drinker 70 57.9 168 69.4 22 64.7 46 68.7 75 57.3 149 57.5 
Hepatitis B positive (N, % ) 16 13.2 5 2.1 0 0 3 4.5 3 2.3 11 4.3 
Hepatitis C positive (N,%  ) 24 19.8 6 2.5 0 0 1 1.5 3 2.3 3 1.2 
Missing values were not excluded from percentage calculations, thus the sum of percents across sub-groups may not add up to 100%. 
Categorical variables are presented as numbers and percentages. 
Continuous variables are presented as mean and standard deviations, except for liver function tests that are presented as medianand5, 95 %). 
a Number of cases and controls with missing variable value: HCC = 3, IHBC = 5, and EBD = 3. 
b Number of cases and controls with missing variable value: HCC = 96, IHBC = 32, and EBD = 147. 
cTotal physical activity categories were sex-specific. Number of cases and controls with missing variable value: HCC = 13, IHBC = 7, and EBD = 18. 
 
  
Supplementary table 2: Spearman correlations for liver biomarkers and selected potential confounders in the controls (n=722). 
  GGT 
(U/L) 
AST 
(U/L) 
ALT 
(U/L) 
ALP 
(U/L) 
Bilirubi
n 
(U/L) 
Albumin 
(g/L) 
CRP 
(mg/dL) 
BMI 
(kg/m2) 
WHR Alcohol 
intake at 
recruitment 
(g/d) 
Coffee 
intake 
(g/d) 
Energy 
intake 
(kcal/d) 
GGT (U/L), ρ 1            
 p             
AST(U/L) , ρ 0.43 1           
 p <.0001            
ALT (U/L) , ρ 0.58 0.69 1          
 p <.0001 <.0001           
ALP (U/L) , ρ 0.28 0.16 0.29 1         
p <.0001 0.000 <.0001          
Bilirubin (g/L) , ρ 0.08 0.03 0.07 -0.03 1        
 p 0.051 0.427 0.095 0.444         
Albumin (g/L) , ρ 0.13 0.17 0.17 0.08 0.17 1       
 p 0.002 <.0001 <.0001 0.045 <.0001        
CRP (mg/dL) , ρ 0.21 0.11 0.18 0.27 -0.11 -0.04 1      
 p <.0001 0.009 <.0001 <.0001 0.011 0.310       
BMI (kg/m2) , ρ 0.16 0.04 0.28 0.18 -0.08 0.00 0.26 1     
 p <.0001 0.317 <.0001 <.0001 0.064 0.935 <.0001      
WHR, ρ 0.21 0.08 0.27 0.17 -0.03 0.06 0.24 0.50 1    
 p <.0001 0.057 <.0001 <.0001 0.452 0.169 <.0001 <.0001     
Alcohol intake at recruitment (g/d) , ρ 0.24 0.17 0.07 -0.06 0.16 0.09 -0.01 -0.07 -0.03 1   
 p <.0001 <.0001 0.112 0.185 <.0001 0.029 0.820 0.111 0.456    
Coffee intake (g/d) , ρ 0.05 0.00 -0.03 -0.02 -0.08 0.05 -0.03 -0.07 -0.04 0.11 1  
 p 0.240 0.954 0.412 0.605 0.060 0.220 0.454 0.099 0.322 0.006   
Energy intake (kcal/d) , ρ 0.01 0.02 0.01 -0.01 0.00 -0.16 -0.07 -0.02 -0.06 0.20 0.08 1 
p 0.726 0.670 0.789 0.729 0.935 0.000 0.105 0.678 0.169 <.0001 0.061  
Spearman correlations (ρ) were conducted after adjustment for sex, age, fasting status, prevalent hepatitis infection and cigarette smoking. 
Supplementary table 3: Serum gamma-glutamyltransferase (GGT) concentrations (IU/L) according to categories of various 
predictor variables among controls in the EPIC nested case-control study, 1992-2004 (men, n= 410 and women, n = 312). 
Stratum (GGT) 
Women (N = 312) Men (N = 410) 
N Geometric mean 95% CI P-value N 
Geometric 
mean 95% CI P-value 
Total 312 20.4 18.6 22.4 --- 410 29 26.4 31.7 <0.0001a 
Age at blood collection, years 
≤55 75 18.3 15.6 21.5 0.190 115 31.9 26.8 38.0 0.533 
55-60 69 21.8 18.5 25.8 105 29.7 25.1 35.0 
61-65 113 23.0 20.0 26.6 120 31.4 26.5 37.3 
>65 55 21.0 17.5 25.2 70 29.0 23.6 35.5 
Cigarette smoking b 
Never 188 23.7 20 28.1 0.263 123 32.7 28.2 37.8 0.729 
Former 62 20.5 18.2 23.1 176 29.2 24.8 34.3 
Current 59 21.8 18.2 26.1 106 28.5 24.1 33.6 
Alcohol consumption at recruitment, g/d 
None 62 20.3 17 24.3 0.118 19 26.5 19.6 36 0.031 
0.1-6 129 20.9 18.3 23.9 98 27.5 23.2 32.7 
6.1-12 46 20 16.5 24.2 57 26.6 21.8 32.5 
12.1-24 55 22.5 18.7 27 103 29.1 24.8 34 
24.1-60 20 26.0 19.4 34.7 97 37.3 31.4 44.3 
>60 36 26.5 19.6 36 
Drinking history 
Never drinker 46 21.2 17.1 26.1 0.812 12 25.9 17.3 38.8 0.411 
Former drinker 14 18.3 13.2 25.4 7 26.0 15.6 43.2 
Drinker at recruitment 83 21.8 18.1 26.2 84 26.3 20.7 33.4 
Lifetime drinker 169 21.5 18.8 24.6 307 32.4 27.7 38.0 
Body mass index, kg/m2 
≤ 25 125 19.1 16.6 21.9 0.115 136 26.1 22.4 30.5 0.008 
25-30 129 23 20.2 26.3 203 32.1 27.9 37 
≥ 30 58 22.3 18.8 26.5 71 33.9 28 41.2 
Waist to hip ratio d 
Tertile 1 87 16.6 14.2 19.4 0.0003 103 23.8 19.9 28.5 <.0001 
Tertile 2 122 19.8 17.2 22.9 171 32.1 27.1 38.1 
Tertile 3 82 24.6 21.2 28.6 128 35.2 29.3 42.3 
Coffee consumption, cups/day e 
None  19 21.1 16.0 28.0 0.343 21 27.9 20.6 37.8 0.620 
<=1 90 22.9 19.2 27.3 110 30.8 26.1 36.4 
>1-3 86 22.6 19.2 26.6 94 34.3 28.7 41.1 
>3-5 65 18.9 15.7 22.7 81 30.5 25.0 37.2 
>5 52 19.1 15.3 24.0 104 25.4 20.8 31.1 
Prevalent diabetes f 
No 284 21.1 16 27.9 0.350 363 30.2 26.5 34.4 0.968 
Yes 14 24.1 20.6 28.1 27 30.1 22.9 39.4 
Prevalent CVD g 
No 150 20.5 17.3 24.3 0.800 223 29.2 25 34.2 0.701 
Yes 85 24.2 20.1 29.2 114 30.1 25.4 35.7 
Alanine aminotransferase (ALT), U/L 
≤55 307 20.6 18.6 22.8 <.0001 398 30.1 26.5 34.2 0.035 
>55 5 70.6 42.1 118 12 45 30.6 66.2 
Aspartate aminotransferase (AST), U/L 
≤34 303 20.2 18.3 22.4 <.0001 385 28 24.8 31.6 <.0001 
>34 9 64.4 44.1 94.2 25 72.7 56.2 94 
C-reactive protein (CRP), mg/L 
≤3 236 19.9 17.9 22.2 0.0002 313 28.1 24.5 32.2 0.002 
>3 76 25.9 22 30.5 97 35.7 30.3 42 
Hepatitis B infection 
No 303 21.2 19.1 23.5 0.674 395 30.2 26.6 34.4 0.260 
Yes 9 19.4 12.7 29.5 14 37.3 25.4 54.8 
Hepatitis C infection 
No 304 21.1 19 23.5 0.970 405 30.5 26.8 34.6 0.195 
Yes 8 21 13.6 32.5 5 20.7 11.5 37.5 
Hepatitis B or C infection h 
No 296 21.2 19.1 23.5 0.640 390 30.3 26.6 34.5 0.788 
  Yes 16 19.7 14.3 27.1   19 31.6 22.6 44.2   
a P-value for comparison of ln(GGT) values between men and women, adjusted for fasting status, BMI and country 
b Missing N=8 
c Missing N = 164 
d Missing N = 29 (women=21, men=8). Sex-specific tertiles (men: ≤0.92, 0.92-0.97, ≥0.97; women:≤ 0.77, 0.77-0.84, ≥ 0.84). 
e Based on the assumption that 1 cup = 150 mL; 
f Self-reported; missing N = 34 
g Self-reported; missing N = 150 
h The numbers of hepatitis B and C infected do not add up because one person had both, hepatitis B and C infections. 
 
  
Supplementary table 4: Serum alanine aminotransferase (ALT) concentrations (IU/L) according to categories of various 
predictor variables among controls in the EPIC nested case-control study, 1992-2004 (men, n= 410 and women, n = 312). 
Stratum (ALT) 
Women (N = 312) Men (N = 410) 
N Geometric mean 95% CI P-value  N 
Geometric 
mean 95% CI P-value 
Total 312 15.1 14.1 16.1 --- 410 19.1 17.9 20.3 <0.0001a 
Age at blood collection, years 
≤55 75 14.5 12.9 16.4 0.5463 115 20.8 18.4 23.5 0.0004 
55-60 69 16.7 14.8 19.0 105 20.4 18.1 22.9 
61-65 113 16.3 14.7 18.1 120 19.6 17.4 22.1 
>65 55 14.2 12.4 16.3 70 15.5 13.4 17.9 
Cigarette smoking b 
Never 188 17.4 15.4 19.7 0.013 123 19.5 17.6 21.5 0.021 
Former 62 14.9 13.7 16.3 176 20.6 18.4 23.0 
Current 59 13.8 12.1 15.8 106 17.5 15.6 19.6 
Alcohol consumption at recruitment, g/d 
None 62 20.3 17 24.3 0.118 19 26.5 19.6 36 0.031 
0.1-6 129 20.9 18.3 23.9 98 27.5 23.2 32.7 
6.1-12 46 20 16.5 24.2 57 26.6 21.8 32.5 
12.1-24 55 22.5 18.7 27 103 29.1 24.8 34 
24.1-60 20 26.0 19.4 34.7 97 37.3 31.4 44.3 
>60 36 26.5 19.6 36 
Drinking history 
Never drinker 46 21.2 17.1 26.1 0.812 12 25.9 17.3 38.8 0.411 
Former drinker 14 18.3 13.2 25.4 7 26.0 15.6 43.2 
Drinker at recruitment 83 21.8 18.1 26.2 84 26.3 20.7 33.4 
Lifetime drinker 169 21.5 18.8 24.6 307 32.4 27.7 38.0 
Body mass index, kg/m2 
≤ 25 125 13.1 11.9 14.5 <.0001 136 16.1 14.5 18.0 <.0001 
25-30 129 16.7 15.2 18.4  203 19.9 18.1 22.0 
≥ 30 58 17.7 15.6 20.0 71 23.4 20.5 26.8 
Waist to hip ratio d 
Tertile 1 87 14.5 12.9 16.2 0.0016 103 23.8 19.9 28.5 <.0001 
Tertile 2 122 15.7 14.1 17.4 171 32.1 27.1 38.1 
Tertile 3 82 17.1 15.3 19.1 128 35.2 29.3 42.3 
Coffee consumption, cups/day e 
None  19 16.0 13.1 19.7 0.3729 21 21.8 17.7 26.9 0.0933 
<=1 111 15.8 13.9 18.0 144 19.2 17.1 21.5 
>1-3 68 15.3 13.6 17.3 66 19.9 17.6 22.5 
>3-5 114 14.7 12.8 16.8 179 19.1 16.7 21.9 
>5 52 14.6 12.4 17.2 104 17.4 15.2 20.0 
Prevalent diabetes f 
No 284 15.1 13.9 16.3 0.972 363 19.0 17.4 20.8 0.284 
Yes 14 15.2 11.9 19.3 27 20.9 17.4 25.1 
Prevalent CVD g 
No 150 15.2 13.4 17.1 0.071 223 18.8 16.9 20.9 0.563 
Yes 85 17.1 15.0 19.6 114 19.4 17.3 21.8 
Gamma glutamyltransferase (GGT), U/L 
≤36/64 247 13.9 12.9 14.9 <.0001 228 16.1 14.8 17.6 <.0001 
>36/64 65 21.7 19.4 24.2 182 24.0 21.9 26.3 
C-reactive protein (CRP), mg/L 
≤3 236 19.9 17.9 22.2 0.0002 313 28.1 24.5 32.2 0.002 
>3 76 25.9 22 30.5 97 35.7 30.3 42 
Hepatitis B infection 
No 303 15.2 14.1 16.5 0.573 395 19.1 17.5 20.9 0.162 
Yes 9 16.6 12.2 22.6 14 22.9 17.6 29.7 
Hepatitis C infection 
No 304 21.1 19 23.5 0.970 405 30.5 26.8 34.6 0.195 
Yes 8 21 13.6 32.5 5 20.7 11.5 37.5 
Hepatitis B or C infection h 
No 296 15.2 14.1 16.4 0.606 390 19.1 17.5 20.9 0.275 
  Yes 16 16.2 12.8 20.4 19 21.6 17.2 27.1 
a P-value for comparison of ln(ALT) values between men and women, adjusted for fasting status, BMI and country 
b Missing N=8 
c Missing N = 164 
d Missing N = 29 (women=21, men=8). Sex-specific tertiles (men: ≤0.92, 0.92-0.97, ≥0.97; women:≤ 0.77, 0.77-0.84, ≥ 0.84). 
e Based on the assumption that 1 cup = 150 mL; 
f Self-reported; missing N = 34 
g Self-reported; missing N = 150 
h The numbers of hepatitis B and C infected do not add up because one person had both, hepatitis B and C infections. 
 
 
 
 
 
 
 
 
 
  
 Supplementary table 5: Serum aspartate aminotransferase (AST) concentrations (IU/L) according to categories of various 
predictor variables among controls in the EPIC nested case-control study, 1992-2004 (men, n= 410 and women, n = 312). 
Stratum (AST) 
Women (N = 312) Men (N = 410) 
N Geometric mean 95% CI P-value  N 
Geometric 
mean 95% CI P-value 
Total 312 18.0 17.2 18.8  410 19.8 18.9 20.7 0.0001a 
Age at blood collection, years 
≤55 75 17.5 16.3 18.8 0.1381 115 20.0 18.3 21.8 0.4559 
55-60 69 17.8 16.6 19.2 105 21.0 19.3 22.8 
61-65 113 19.0 17.8 20.3 120 19.8 18.2 21.6 
>65 55 18.6 17.1 20.2 70 19.3 17.5 21.4 
Cigarette smoking b 
Never 188 20.0 18.5 21.6 0.011 123 20.8 19.3 22.4 0.012 
Former 62 18.1 17.2 19.1 176 20.8 19.2 22.6 
Current 59 17.3 16.0 18.8 106 18.6 17.2 20.2 
Alcohol consumption at recruitment, g/d 
None 62 17.7 16.3 19.1 0.3045 19 18.2 15.6 21.2 0.0133 
0.1-6 129 18.4 17.3 19.6  98 19.6 17.9 21.3 
6.1-12 46 18.5 17.0 20.2 57 19.6 17.7 21.6 
12.1-24 55 18.3 16.9 19.9 103 19.8 18.3 21.4 
24.1-60 20 19.2 16.8 22.0 97 22.4 20.6 24.4 
>60 36 21.0 18.5 23.7 
Drinking history 
Never drinker 46 17.5 15.9 19.2 0.378 12 18.2 14.9 22.2 0.394 
Former drinker 14 17.6 15.2 20.4 7 17.7 13.7 22.8 
Drinker at recruitment 83 17.7 16.2 19.2 84 19.4 17.2 21.8 
Lifetime drinker 169 18.9 17.8 20.1 307 20.7 19.1 22.3 
Body mass index, kg/m2 
≤ 25 125 18.0 16.9 19.1 0.7783 136 19.0 17.6 20.6 0.0052 
25-30 129 18.7 17.6 19.8 203 20.4 19.0 21.9 
≥ 30 58 18.2 16.8 19.7 71 21.8 19.8 24.0 
Waist to hip ratio d 
Tertile 1 87 18.1 16.8 19.5 0.4143 103 20.1 18.4 22.1 0.0433 
Tertile 2 122 18.3 17.1 19.5 171 19.5 17.9 21.3 
Tertile 3 82 19.1 17.8 20.5 128 21.2 19.3 23.4 
Coffee consumption, cups/day e 
None  19 18.1 15.9 20.6 0.5022 21 22.5 19.3 26.1 0.0153 
<=1 111 19.3 17.8 20.9 144 20.6 18.9 22.3 
>1-3 68 18.3 17.0 19.7 66 20.7 18.9 22.6 
>3-5 114 17.5 16.1 19.0 179 19.7 17.9 21.7 
>5 17.8 16.1 19.8 18.1 16.4 20.0 
Prevalent diabetes f 
No 284 18.4 17.5 19.4 0.018 363 20.2 18.9 21.6 0.575 
Yes 14 15.3 13.2 17.8 27 19.5 17.0 22.3 
Prevalent CVD g 
No 150 17.4 16.1 18.8 0.051 223 19.8 18.3 21.4 0.415 
Yes 85 18.9 17.4 20.6 114 20.4 18.8 22.2 
Gamma glutamyltransferase (GGT), U/L 
≤36/64 247 17.3 16.5 18.1 <.0001 228 18.2 17.1 19.4 <.0001 
>36/64 65 22.5 21.0 24.1 182 23.1 21.5 24.7 
C-reactive protein (CRP), mg/L 
≤3 236 18.0 17.1 18.9 0.042 313 19.9 18.6 21.3 0.274 
>3 76 19.4 18.0 20.9 97 20.8 19.1 22.5 
Hepatitis B infection 
No 303 18.3 17.4 19.2 0.058 395 20.2 18.9 21.5 0.442 
Yes 9 21.9 18.1 26.5 14 21.7 17.9 26.2 
Hepatitis C infection 
No 304 18.3 17.4 19.2 0.371 405 20.2 18.9 21.5 0.667 
Yes 8 20.0 16.4 24.4 5 21.5 16.0 28.9 
Hepatitis B or C infection h 
No 296 18.3 17.4 19.2 0.458 390 20.2 18.9 21.5 0.369 
  Yes 16 19.3 16.7 22.3 19 21.7 18.3 25.6 
a P-value for comparison of ln(GGT) values between men and women, adjusted for fasting status, BMI and country 
b Missing N=8 
c Missing N = 164 
d Missing N = 29 (women=21, men=8). Sex-specific tertiles (men: ≤0.92, 0.92-0.97, ≥0.97; women:≤ 0.77, 0.77-0.84, ≥ 0.84). 
e Based on the assumption that 1 cup = 150 mL; 
f Self-reported; missing N = 34 
g Self-reported; missing N = 150 
h The numbers of hepatitis B and C infected do not add up because one person had both, hepatitis B and C infections. 
 
 
 
 
 
 
 
 
 
 
  
Supplementry  table 6: Serum Alkaline phosphatase (ALP) concentrations (IU/L) according to categories of various predictor 
variables among controls in the EPIC nested case-control study, 1992-2004 (men, n= 410 and women, n = 312). 
Stratum (ALP) 
Women (N = 312) Men (N = 410) 
N Geometric mean 95% CI P-value  N 
Geometric 
mean 95% CI P-value 
Total 312 64.1 61.3 66.9 --- 410 59.3 56.9 61.9 0.0011 
Age at blood collection, years 
≤55 75 55.9 51.1 61.2 0.0047 115 59.9 56.0 64.2 0.9699 
55-60 69 66.6 60.7 73.1 105 61.0 57.1 65.1 
61-65 113 70.0 64.6 75.8 120 59.0 55.2 63.0 
>65 55 67.1 60.5 74.3 70 60.7 56.0 65.7 
Cigarette smoking b 
Never 188 64.1 58.2 70.5 0.276 123 58.7 55.4 62.2 0.079 
Former 62 63.6 59.4 68.0 176 60.0 56.3 63.9 
Current 59 69.0 62.3 76.4 106 63.1 59.1 67.3 
Alcohol consumption at recruitment, g/d 
None 62 67.9 61.4 75.1 0.447 19 65.5 58.0 74.0 0.0232 
0.1-6 129 64.7 60.0 69.7 98 62.3 58.1 66.7 
6.1-12 46 62.5 56.0 69.6 57 62.3 57.5 67.4 
12.1-24 55 64.0 57.7 71.0 103 59.0 55.4 62.8 
24.1-60 20 63.3 53.7 74.6 97 57.7 53.9 61.8 
>60 36 60.3 54.6 66.5 
Drinking history 
Never drinker 46 71.1 63.1 80.2 0.400 12 62.8 53.7 73.5 0.500 
Former drinker 14 63.0 52.4 75.8 7 69.2 56.7 84.3 
Drinker at recruitment 83 67.2 60.5 74.7 84 60.2 54.9 66.1 
Lifetime drinker 169 63.4 58.7 68.4 307 59.8 56.2 63.6 
Body mass index, kg/m2 
≤ 25 125 59.3 54.9 64.1 0.0004 136 60.3 56.8 64.1 0.2926 
25-30 129 67.3 62.5 72.4 203 59.4 56.2 62.8 
≥ 30 58 72.6 65.8 80.0 71 62.8 58.2 67.7 
Waist to hip ratio d 
Tertile 1 87 56.3 51.7 61.4 <.0001 103 58.4 54.3 62.9 0.1524 
Tertile 2 122 62.9 58.2 68.0 171 59.5 55.6 63.8 
Tertile 3 82 68.6 63.2 74.4 128 61.4 56.9 66.4 
Coffee consumption, cups/day e 
None  19 67.3 57.5 78.7 0.9154 21 61.2 54.4 68.8 0.1906 
<=1 111 61.2 55.5 67.6 144 61.1 57.3 65.2 
>1-3 68 68.9 62.9 75.5 66 60.9 56.8 65.2 
>3-5 114 61.7 55.7 68.4 179 63.2 58.6 68.3 
>5 67.9 59.9 76.9 54.4 50.3 58.8 
Prevalent diabetes f 
No 284 63.8 60.0 67.9 0.009 363 60.1 57.1 63.2 0.804 
Yes 14 82.3 68.2 99.4 27 60.8 54.7 67.6 
Prevalent CVD g 
150 62.8 62.8 57.2 69.0 0.023 223 59.4 55.9 63.2 0.415 
85 70.7 70.7 63.7 78.4 114 59.8 55.9 63.9 
Gamma glutamyltransferase (GGT), U/L 
≤36/64 247 62.3 58.6 66.2 0.0001 228 57.2 54.2 60.4 <0.0001 
>36/64 65 74.5 67.9 81.6 182 64.5 61.0 68.3 
C-reactive protein (CRP), mg/L 
≤3 236 62.5 58.8 66.5 0.001 313 57.9 54.9 61.0 <0.0001 
>3 76 72.8 66.4 79.7 97 65.6 61.6 69.8  
Hepatitis B infection 
No 303 64.7 61.0 68.6 0.729 395 60.3 57.4 63.5 0.469 
Yes 9 67.4 53.2 85.4 14 57.2 49.2 66.5 
Hepatitis C infection 
No 304 64.8 61.1 68.8 0.672 405 60.4 57.4 63.5 0.370 
Yes 8 61.5 48.1 78.6 5 54.4 43.1 68.6 
Hepatitis B or C infection h 
No 296 64.7 61.0 68.6 0.855 390 60.4 57.5 63.5 0.266 
  Yes 16 65.8 55.0 78.7 19 56.3 49.4 64.2 
a P-value for comparison of ln(GGT) values between men and women, adjusted for fasting status, BMI and country 
b Missing N=8 
c Missing N = 164 
d Missing N = 29 (women=21, men=8). Sex-specific tertiles (men: ≤0.92, 0.92-0.97, ≥0.97; women:≤ 0.77, 0.77-0.84, ≥ 0.84). 
e Based on the assumption that 1 cup = 150 mL; 
f Self-reported; missing N = 34 
g Self-reported; missing N = 150 
h The numbers of hepatitis B and C infected do not add up because one person had both, hepatitis B and C infections. 
  
 Supplementary table 7. Association for liver function biomarkers (per 1SD logarithm transformed values) and liver function 
score with HCC risk separate for men and women. 
 HCC (ncases=121) Model 1 
  
  
Model 2 
  
  
Model 3 
  
  
Men (ncases=82) OR 95% CI 
  
OR 95% CI 
  
OR 95% CI 
  
GGT 6.09 3.38, 10.94 5.84 3.01,11.33 4.57 2.36,8.84 
ALT 2.88 1.97, 4.21 3.01 1.87,4.84 2.10 1.28,3.46 
AST 4.08 2.60, 6.41 4.26 2.42,7.50 3.25 1.80,5.88 
ALP 4.46 2.71,7.35 4.39 2.33,8.27 4.86 2.21,10.70 
Bilirubin 2.12 1.50,2.98 2.59 1.61,4.18 2.13 1.29,3.52 
Liver function scorea 4.25 2.55,7.08 4.00 2.32,6.92 3.35 1.91,5.87 
Women (ncases=37)  
GGT 3.03 1.70,5.40 3.03 1.70,5.40 3.68 1.39,9.73 
ALT 2.55 1.51,4.32 2.55 1.51,4.32 2.20 0.98,4.92 
AST 3.33 1.73,6.43 3.33 1.73,6.43 2.81 1.12,7.01 
ALP 2.09 1.30,3.35 2.09 1.30,3.35 2.89 1.25, 6.65 
Bilirubin 1.89 1.15,3.09 1.89 1.15,3.09 2.01 0.94,4.32 
Liver function score 2.56 1.55,4.23 3.27 1.50,7.15 2.67 1.13,6.32 
Model 1: matching factors 
Model 2: model 1 adjusted for BMI continuous alcohol at recruitment continuous, drinking history, smoking status, physical
activity 
Model 3: model 2 + plus hepatitis 
a Ranges from 0 to 6; based on abnormal liver function tests (ALT>55 U/L, AST>34 U/L, GGT men >64 U/L, GGT 
women > 36 U/L, ALP > 150 U/L, albumin < 34 g/L, total bilirubin > 20.5 μmol/L; values were provided by the 
laboratory). 
 
  
 Supplementary table 8. Association for liver function biomarkers (per 1SD logarithm transformed values) and liver function 
score with GBTC risk separate for men and women. 
GBTC (ncases=131) Model 1 
  
  
Model 2 
  
  
Men (ncases=58) OR 95% CI 
  
OR 95% CI 
  
GGT 1.54 0.93,2.54 1.43 0.95,2.13 
ALT 1.07 0.49,2.33 0.96 0.64,1.45 
AST 1.43 0.52,3.92 1.09 0.77,1.53 
ALP 14.84 3.16,69.80 2.33 1.31,4.17 
Bilirubin 0.78 0.35,1.72 0.95 0.65,1.40 
Liver function scorea 1.12 0.64,1.95 1.17 0.62,2.20 
Women (ncases=73)   
GGT 1.11 0.65,1.91 1.00 0.68,1.47 
ALT 1.40 0.69,2.86 1.19 0.84,1.69 
AST 1.61 0.49,5.30 1.20 0.82,1.74 
ALP 2.21 0.83,5.87 1.33 0.96,1.85 
Bilirubin 1.32 0.62,2.83 1.17 0.83,1.66 
Liver function score 1.05 0.57,1.95 1.02 0.53,1.94 
Model 1: matching factors 
Model 2: model 1 adjusted for BMI continuous alcohol at recruitment continuous, drinking history, smoking status, physical activity 
a Ranges from 0 to 6; based on abnormal liver function tests (ALT>55 U/L, AST>34 U/L, GGT men >64 U/L, GGT women > 36 U/L, 
ALP > 150 U/L, albumin < 34 g/L, total bilirubin > 20.5 μmol/L; values were provided by the laboratory). 
 
Supplementary table 9. HCC, IHBC and GBTC risk by categories of HSI, liver function score, AST/ALT and GGT/ALP ratios. 
    HSI category a Liver function score 
category b 
  
  
AST/ALT ratio  
category c 
  
  
GGT/ALP ratio  
category d 
  
  
  OR 95% CI 
 
OR 95% CI 
 
OR 95% CI 
 
OR 95% CI 
 
HCC (ncases=121) Model 1 1.20 0.78, 1.86 9.35 5.27, 16.58 4.53 1.59,12.94 10.86 3.17,37.15 
  Model 2 0.92 0.46, 1.84 8.61 4.50,16.46 5.36 1.49,19.35 8.68 2.25,33.50 
IHBCd (ncases=35) Model 1 2.95 1.18, 7.33 3.53 1.33,9.40 - - - - 
  Model 2 2.76 0.60, 12.79 4.45 1.17,16.98 - - - - 
GBTCe (ncases=131) Model 1 1.00 0,64, 1.59 0.97 0.52,1.80 1.70 0.54,5.39 0.50 0.06,4.47 
  Model 2 0.72 0.37, 140 0.92 0.49,1.73 2.07 0.61,7.01 0.59 0.06,5.79 
HCC, hepatocellular carcinoma; IHBC, intrahepatic bile duct cancer; GBTC, gallbladder and biliary tract cancer 
 
a Hepatic steatosis index (HSI) = 8 x ALT/AST ratio +BMI (+2, if diabetes;  +2; if female), HSI<36 (reference; liver steatosis unlikely) and ≥36 (suspected liver steatosis) 
b Liver function score is based on abnormal liver function tests (ALT>55 U/L, AST>34 U/L, GGT men >64 U/L, GGT women > 36 U/L, ALP > 150 U/L, albumin < 34 g/L, 
total bilirubin > 20.5 μmol/L; values were provided by the laboratory). The liver function score was grouped into two categories:  0 (reference) or 1 -6 abnormal liver function 
tests. 
c AST/ALT ratio categories: ≤2 (reference) and >2; ratio > 2 may signalise alcoholic liver disease 
d AST/ALT ratio categories: ≤2.5 (reference) and >2.5; ratio >2.5 may indicate liver cirrhosis 
e not enough subjects in the upper category for AST/ALP ratio (n=2) and GGT/ALP ratio (n=1)  
 
 
 
 
 
SUPPLEMENTARY FIGURES 
 
Supplementary Fig. 1:  Loess curves for HCC of log-transformed standardised levels (rescaled to have a mean of 0 and a SD of 1) of liver biomarkers (GGT, AST, ALT, 
ALP, bilirubin and AFP) by the time of follow up. Follow up time length of the HCC cases was assigned to their controls for better visualization of the data.  
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Supplementary Fig. 2. Area under receiver operating characteristic curve (AUROC) based only on stepwise 
selection of liver function biomarkers and corresponding sensitivity and specificity in validation data. 
 
  
  AUROC (95% CI)  Sensitivity 
(true positive rate) 
Specificity 
(false positive rate) 
GGT, AST, ALT  0.88 (0.82, 0.94)  0.78  0.81 
 
AUROC displays the discriminatory accuracy for predicting the development of HCC. Independent liver function 
biomarkers were selected with a stepwise selection method based on c-statistic. Sensitivity indicates the 
probability of correctly selecting prospective HCC cases. Specificity indicates the probability of correctly selecting 
controls. Red points indicate the threshold probabilities for which sensitivity and specificity points were selected 
based on the shortest distance for a perfect marker.  
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Supplementary Fig. 3 Cubic splines for the dose-response associations for log-transformed levels of 
ALT, ALP, AST and Bilirubin and HCC risk. Adjusted OR and 95%CI (dashed lines) were 
constructed with 3 knots with the reference value set as median.  
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